Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14912329 | 1.00 | KDM4E (0.45) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL14912096 | 0.79 | BACE1 (0.50) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL14912093 | 0.79 | BACE1 (0.50) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL11517006 | 0.78 | S1PR4 (0.45) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL3597858 | 0.78 | TDP1 (0.48) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL19643476 | 0.77 | KDM4E (0.62) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL19643475 | 0.77 | KDM4E (0.62) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL14912427 | 0.76 | HDAC8 (0.59) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL14912423 | 0.76 | HDAC8 (0.59) | KDM4EMEN1KMT2ALMNARAB9A | |
| SCHEMBL5412134 | 0.75 | RAB9A (0.66) | KDM4EMEN1KMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657034-B2 | Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors | AbbVie Deuschland GmbH & Co. KG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2776418-B1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-01-04 | — | — | EP | disclosed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | disclosed |
| US-9273068-B2 | Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-01 | — | — | US | disclosed |
| EP-2776418-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| CN-104053654-A | Inhibitors Of Phosphodiesterase Type 10a | ABBVIE GMBH & CO KG | 2014-09-17 | — | — | CN | disclosed |
| WO-2013068470-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | WO | disclosed |
| US-20130116241-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116233-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | KDM4E 803/4885MEN1 1923/4885KMT2A 2616/4885 |
| US-20130116241-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | KDM4E 803/4885MEN1 1923/4885KMT2A 2616/4885 |
| US-20130116233-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | KDM4E 1619/4885MEN1 2739/4885KMT2A 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.